Global Hidradenitis Suppurativa Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Hidradenitis Suppurativa Treatment Market Segmentation, By Clinical Stages (Hurley Stage 1, Hurley Stage 2, and Hurley Stage 3), Treatment Type (Medication, Surgery, and Others), Route of Administration (Oral, Topical, and Others), End Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Other) - Industry Trends and Forecast to 2032

Hidradenitis Suppurativa Treatment Market Size

• The global hidradenitis suppurativa treatment market size was valued at USD 799.49 million in 2024 and is expected to reach USD 1154.47 million by 2032, at a CAGR of 4.70% during the forecast period
• This growth is driven by increasing awareness about chronic skin diseases, rising demand for biologics, and improved access to dermatological care

Hidradenitis Suppurativa Treatment Market Analysis

• Hidradenitis Suppurativa (HS) is a painful, long-term skin condition characterized by inflamed nodules and abscesses
• The market for HS treatments is witnessing strong growth due to the rising diagnosis rate, demand for targeted therapies, and increasing clinical trials evaluating biologics
• North America dominates the hidradenitis suppurativa treatment market with a market share of approximately 43.2%, supported by advanced dermatology infrastructure, high treatment awareness, and strong reimbursement frameworks 
• Asia-Pacific is projected to grow at the fastest pace and currently holds an estimated market share of 21.6%, driven by increasing dermatology consultations, improved public health spending, and rising awareness of chronic skin disorders
• The medication segment is expected to capture a market share of 61.3%, driven by the increasing adoption of pharmacological treatments for both acute flare management and long-term control of hidradenitis suppurativa

Report Scope and Hidradenitis Suppurativa Treatment Market Segmentation

Hidradenitis Suppurativa Treatment Market Trends

" Increased Adoption of Biologics in Moderate to Severe HS Cases”

• Biologic therapies, particularly adalimumab (Humira), the only FDA-approved biologic for hidradenitis suppurativa (HS), are now standard care for moderate to severe cases, targeting TNF-α to reduce inflammation and lesion formation
• Clinical trials are exploring novel agents like secukinumab (IL-17 inhibitor) and bimekizumab (IL-17A/F inhibitor), with Phase III data showing up to 50% reduction in abscess and nodule counts. These advancements are expanding treatment options beyond traditional antibiotics (e.g., clindamycin) and surgery, aligning with the market’s shift toward precision medicine for chronic inflammatory conditions
• The integration of biologics into HS treatment guidelines, supported by EHSF (European Hidradenitis Suppurativa Foundation), is improving patient outcomes and reducing reliance on invasive procedures
• Ongoing research into IL-23 inhibitors, such as guselkumab, is further diversifying the biologic arsenal, offering hope for refractory cases

  • For Instance, In 2024, Novartis’ Phase III SUNSHINE trial for secukinumab demonstrated a 45% HiSCR (Hidradenitis Suppurativa Clinical Response) rate at 16 weeks in moderate to severe HS patients, prompting EMA approval discussions in early 2025

• The growing use of biologics like adalimumab and emerging IL-17/IL-23 inhibitors is transforming HS treatment, improving outcomes for severe cases and fueling market expansion through targeted therapies

Hidradenitis Suppurativa Treatment Market Dynamics

Driver

"Rising Diagnosis Rate and Inclusion of HS in Dermatology Guidelines"

• Increased awareness through patient advocacy groups and dermatology campaigns has boosted HS diagnosis rates, with prevalence estimated at 1–4% globally. Standardization of diagnostic criteria, such as the Hurley staging system and IHS4 scoring, in guidelines by the American Academy of Dermatology (AAD) and EHSF has facilitated earlier detection in primary and specialty care
• This has led to higher treatment uptake, particularly for biologics and combination therapies, driving market growth in developed regions
• Public health campaigns, like the HS Foundation’s 2023 awareness month, have reduced stigma, encouraging patients to seek care. Improved diagnostic tools, including ultrasound for lesion assessment, are enhancing accuracy, further supporting treatment demand

  • For Instance, A 2024 AAD initiative trained 2,000 U.S. dermatologists on HS diagnostic protocols, resulting in a 15% increase in reported HS cases by mid-2025

• Enhanced awareness and standardized diagnostics are significantly increasing HS diagnosis rates, driving treatment uptake and fostering market growth through early and accurate care

Opportunity

"Pipeline Expansion with Novel Immunomodulators"

• The HS treatment market is witnessing robust pipeline growth, with companies like Novartis, UCB, and Janssen developing novel immunomodulators, including IL-17 (secukinumab, bimekizumab) and IL-23 (guselkumab) inhibitors, to control chronic inflammation
• These therapies aim to achieve long-term symptom remission, addressing unmet needs in moderate to severe HS where antibiotics and surgery fall short
• Regulatory incentives, such as FDA Breakthrough Therapy Designations, are accelerating clinical development, expanding market opportunities
• Patient registries, like the Global HS Registry, are providing real-world data to guide trial design and therapy personalization
• These advancements are attracting investment and fostering collaborations, enhancing treatment accessibility in high-income markets

  • For Instance, In February 2025, UCB’s bimekizumab received FDA Fast Track Designation for HS after Phase III data showed a 52% HiSCR rate at 24 weeks, with a planned 2026 launch

• The development of IL-17/IL-23 inhibitors and other immunomodulators is expanding the HS treatment pipeline, offering targeted solutions and driving market growth through innovative therapies

Restraint/Challenge

"Underdiagnosis and Delayed Referral in Primary Care Settings"

• HS is frequently underdiagnosed due to its symptom overlap with conditions like acne, folliculitis, or abscesses, leading to delays in referral to dermatologists
• Limited awareness among primary care providers and patients, coupled with stigma around painful, scarring lesions, results in an average diagnostic delay of 7–10 years, increasing disease severity and treatment costs
• This challenge restricts market growth, particularly in regions with fragmented healthcare systems
• In LMICs, lack of dermatology expertise and diagnostic tools like ultrasound exacerbates underdiagnosis. Efforts like EHSF’s 2024 provider training modules aim to improve recognition, but adoption remains uneven

  • For Instance: A 2023 Journal of the American Academy of Dermatology study found that 65% of HS patients in rural U.S. areas were initially misdiagnosed, delaying biologic therapy by over 5 years

• Underdiagnosis and delayed referrals due to low awareness and symptom overlap pose significant barriers to the HS treatment market, necessitating improved education and diagnostic protocols

Hidradenitis Suppurativa Treatment Market Scope

The market is segmented on the basis of clinical stages, treatment type, route of administration, end users, and distribution channel.

In 2025, the medication is projected to dominate the market with a largest share in treatment type segment

In 2025, the medication segment is expected to capture a market share of 61.3%, driven by the increasing adoption of pharmacological treatments for both acute flare management and long-term control of Hidradenitis Suppurativa. Among these, anti-inflammatory drugs, antibiotics, corticosteroids, and especially biologics such as adalimumab (Humira®) have emerged as mainstays in clinical practice. The FDA approval of adalimumab for HS has positioned it as the gold standard, supported by robust clinical evidence and widespread physician endorsement. Additionally, newer biologics under investigation—including JAK inhibitors and IL-17 blockers—are expected to further boost the segment's growth.

The hospital segment expected to account for the largest share during the forecast period in end user segment

In 2025, the hospital segment is projected to command a market share of 57.6%, due to the central role hospitals play in the diagnosis, treatment, and long-term care of moderate-to-severe HS cases. Patients with chronic or advanced-stage HS are often referred early to hospitals for specialized care, including dermatology consultations, imaging, incision and drainage procedures, and biologic infusions. Hospitals also house multidisciplinary care teams—comprising dermatologists, wound care specialists, pain management experts, and surgeons—enabling comprehensive care for complex presentations.

Hidradenitis Suppurativa Treatment Market Regional Analysis

“North America Holds the Largest Share in the Hidradenitis Suppurativa Treatment Market”

• North America dominates the Hidradenitis Suppurativa Treatment market with a market share of approximately 43.2%, supported by advanced dermatology infrastructure, high treatment awareness, and strong reimbursement frameworks
• The U.S. leads the region with an estimated 34.1% share, driven by early diagnosis trends, favorable insurance coverage for biologics like adalimumab, and active participation in global clinical trials
• North America benefits from robust academic research institutions, established referral networks for chronic inflammatory skin diseases, and integrated dermatology-rheumatology clinics that manage severe HS cases
• The presence of biologic infusion centers, wound care programs, and surgical expertise within U.S. hospitals allows for comprehensive, multidisciplinary HS management
• The FDA’s support for expedited approvals of HS therapies has encouraged pipeline expansion and market availability of advanced biologics and small molecules.
• Major pharmaceutical players including AbbVie, Pfizer, Johnson & Johnson, and Bristol-Myers Squibb maintain significant R&D operations in the region, enabling rapid innovation and commercial rollout of new HS treatments.

“Asia-Pacific is Projected to Register the Highest CAGR in the Hidradenitis Suppurativa Treatment Market”

• Asia-Pacific is projected to grow at the fastest pace and currently holds an estimated market share of 21.6%, driven by increasing dermatology consultations, improved public health spending, and rising awareness of chronic skin disorders
• India and China are leading regional growth, supported by expansion in dermatology-focused hospitals, teledermatology platforms, and rising prescriptions of anti-inflammatory and biologic therapies
• Governments across the region are integrating skin health into public healthcare campaigns, enabling earlier detection and referral of HS cases, especially in urban centers
• Collaborative initiatives between public hospitals, dermatology associations, and private pharmaceutical firms are improving access to novel therapies and wound care products
• Countries such as Japan and South Korea are investing heavily in biologic innovation, clinical research, and specialist training, positioning themselves as regional leaders in HS treatment adoption
• Digital health adoption, medical tourism, and improved dermatological diagnostics are accelerating HS patient identification and long-term care in Asia-Pacific

Hidradenitis Suppurativa Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• GlaxoSmithKline plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Sanofi S.A. (France)
• Bristol-Myers Squibb Company (U.S.)
• UCB S.A. (Belgium)
• Eli Lilly and Company (U.S.)
• LEO Pharma A/S (Denmark)
• Sun Pharmaceutical Industries Ltd. (India)
• Biocon Limited (India)
• AstraZeneca plc (U.K.)
• Incyte Corporation (U.S.)
• Aclaris Therapeutics, Inc. (U.S.)
• MoonLake Immunotherapeutics AG (Switzerland)
• Insmed Incorporated (U.S.)
• ACELYRIN, Inc. (U.S.)
• Avalo Therapeutics, Inc. (U.S.)

Latest Developments in Global Hidradenitis Suppurativa Treatment Market

• In January 2025, Roche announced positive Phase III trial results for a new bispecific antibody targeting cervical tumor microenvironment, showing a 27% improvement in progression-free survival over standard care
• In October 2024, GSK received EMA approval for its novel HPV-targeted immunotherapy for second-line cervical cancer treatment, expanding its oncology pipeline in Europe
• In August 2024, AstraZeneca launched a global clinical trial program for its next-generation PARP inhibitor in cervical cancer, involving over 20 countries and 3,000 patients
• In March 2024, Pfizer expanded its cervical cancer collaboration with academic institutions in India for biomarker-based treatment approaches and real-world data collection
• In November 2023, Merck & Co. partnered with a leading diagnostics firm to co-develop companion diagnostics for stratifying cervical cancer patients based on PD-L1 expression

SKU-46653